We investigated the relationship between asthma mortality and long-acting beta 2 -agonists (LABA), including interactions with age, inhaled corticosteroids (ICS) and social deprivation.
Introduction
Concerns that the prescription of inhaled long-acting beta 2 agonists (LABA) might be associated with a higher risk of asthma death were first raised by Castle et al. in 1993. 1 More recently the SMART trial 2e4 found evidence of an increased risk of asthma related death, and 'combined asthma related death or life threatening experiences' among those in the Salmeterol versus the placebo group. For both outcomes the increase was possibly tempered by concomitant use of inhaled corticosteroids (ICS) and for 'combined asthma related death or life threatening experiences', the increase was largely confined to African-Americans. 2, 3 The original analysis of the ADCCS (Asthma Death CaseControl Study 5e7 ) found no evidence of an adverse effect of LABA whether mentioned in the primary care record in the 3 months, > 3e12 months, or > 1e5 years before the index date (date of death for cases and date of hospital admission for controls). Mention of SABA in the > 1e5 years prior was associated with a higher risk of asthma death while mentions of antibiotics in the 3 months and > 1e5 years prior and oral corticosteroids in the 3 months prior were associated with a lower risk of asthma death. 5, 7 However, this analysis had certain limitations 1) potential biases were noted which may have influenced case-control comparisons, particularly in the 3 months prior to index date 2) there was no analysis of the interaction between LABA and ICS and 3) there was no attempt to examine interactions with socioeconomic deprivation.
We have conducted a new, more detailed and quality controlled extraction from the original records and made adjustments for potential biases. Using this dataset, we aim to investigate the association between asthma death and mention of LABA in the 2 and > 2e6 months prior to index date and to consider as possible modifying effects, age, concomitant prescribing with ICS and a socioeconomic deprivation index.
Materials and methods

Study subjects and design
Full details are described in earlier publications. 5e7 The study areas were based on regions participating in confidential inquiries into asthma deaths and covered 27% of the British population (a population in which medical care is provided free of charge at the point of delivery). The case series comprised all asthma deaths aged < 65 years occurring in the study areas of England and Wales between 1994 and 1998 inclusive and in the study areas of Scotland between 1996 and 1998 inclusive. Fixed dose ICS/LABA combination inhalers were not prescribed during the period covered by the study.
All cases had 'asthma' in part 1 of the death certificate with no more credible non-respiratory underlying cause. After exclusions (detailed elsewhere 6, 7 ) , 532 cases were included in the study. For each case, one control was selected from the asthma discharge list of the hospital where the case had died (or the next nearest hospital or, for a community death, the hospital to which the case would have been admitted). The control was selected firstly to have a similar index date to its case (96% within 6 months, maximum difference 13 months) and secondly to be of a similar age (98% within 5 years, maximum age difference 12 years). 6, 7 For each case and control, their primary care record was first anonymised and then photocopied for the 5 years prior to the index date. The Asthma Death Case-Control Study was approved by the South Thames Multi-centre Research Ethics Committee (MREC) in September 1997. Permissions to photocopy anonymised primary care records were obtained in writing from general practitioners.
Methods
Using these photocopied records, nursing/medically qualified personnel conducted a new and more detailed extraction of data on drugs, COPD (i.e. mention of COPD, COAD, chronic bronchitis and emphysema) and other chronic lung diseases. Data were extracted twice in a blinded fashion by different extractors and later reconciled. The same person was allocated to extract information on a case and its matched control.
Deprivation data were obtained by linking, via the National Postcode Directory, 8 the GP post-code of each subject to either a Lower Layer Super Output Area (average population 1500) within England and Wales or a Data Zone (average population 750) within Scotland and thence to a country specific Index of Multiple Deprivation (IMD) and its rank. 9 We used the 2004 index for England, 10 the 2005 index for Wales 11 and the 2006 index for Scotland. 12 Using within country midranks, subjects were categorised according to whether their primary care services were based in a more or less deprived area of England, Scotland or Wales, as appropriate. The way in which the Index of Multiple Deprivation is calculated differs between England, Scotland and Wales but all three measures combine area level information on various aspects of deprivation including income, employment, health and education. 9 The only variables included in the new analysis, but obtained as part of the original study 5e7 were sex, age of asthma onset, mention of obesity ever and number of hospital admissions for asthma in the 1 year and > 1e5 years prior.
Of the 532 cases, 112 (21%) died in hospital after the day of admission. Given the difference in index date definition between cases and controls and the lack of information recorded in the primary care notes during a period of hospital admission, this could lead to bias; a bias that was not adjusted for in the previous analysis. Any data relating to drugs for the period of the index admission (including the day of admission) was therefore removed/censored from the GP record of the case and for an equivalent period from the GP record of its matched control. A similar censoring process was used to deal with the correction of errors in index dates made after the photocopying of the primary care record. As a result, the period of observation prior to the index date was shortened by more than 2 weeks for 52 matched pairs (10%), more than 4 weeks for 28 matched pairs (5%), more than 2 months for 15 matched pairs (3%) and by more than 6 months for 5 matched pairs (1%). Censoring was only implemented in relation to information on drugs and the number of previous hospital admissions for asthma.
Statistical analysis
Data were analysed using conditional logistic regression and the likelihood ratio test. The variables investigated included six main classes of respiratory drugs (inhaled short-acting beta 2 -agonists (SABA), inhaled long-acting beta 2 -agonists (LABA), inhaled corticosteroids (ICS), oral corticosteroids, antimuscarinics and methylxanthenes), two named drugs (Salmeterol and Fenoterol), injected corticosteroids and antibiotics. Fenoterol, an inhaled short-acting beta 2 -agonist, was of interest, as case-control studies of severe asthmatics conducted in New Zealand in the 1970s and 1980s suggested that its prescription was associated with a higher risk of asthma death. 13 For each drug or class, two variables were created representing any mention (yes/no) in the primary care record in the 2 and the > 2e6 months prior to index date. Variables for LABA were further divided by the presence/absence of a concomitant mention (1 month either side but prior to index date) of ICS. The full confounder model included sex, age of asthma onset, ever mention of obesity, mention of COPD in the past 5 years, mention of other chronic lung diseases in the past 5 years, previous admissions for asthma in the past year and the > 1e5 years prior, other main respiratory drug classes, and deprivation rank within country. Quantitative and ordinal variables (including deprivation ranks) were treated in the full confounder model as continuous. Deprivation rank group (less deprived, more deprived) and age group (1e44, 45e64) were used to model and test for interactions.
Our analysis makes the assumption that within a specified period of observation (e.g. 2 months prior to index date), odds ratios do not change with time (e.g. are the same for the 1 month prior and the > 1e2 months prior), and are therefore invariant to loss of data through censoring.
Results
Among the 1064 study subjects only 55 (5.2%) were under the age of 18 years. As reported previously 5e7 and described here in Table 1 , cases and controls were similar with respect to age (median 53 years interquartile range (40e59) in both groups) and female sex (60.2% versus 63.5%) but cases had a significantly (p Z 0.013) earlier median age of asthma onset (30 years (10e47) n Z 493 versus 33 years (13e49) n Z 502) and a higher proportion had mention of obesity ever (30.6% versus 25.0%; p Z 0.037). Mention of other chronic lung diseases (6.0% versus 3.6%) was also significantly (p Z 0.046) higher among cases than controls as was mention of COPD (45.1% versus 38.2%; p Z 0.010), with the latter association differing significantly (p Z 0.020) between the 45e64 age group (60.7% versus 48.9%) and the 1e44 year age group (10.8% versus 14.9%). By contrast similar proportions were mapped by GP post-code to the most deprived areas in England (68.4% versus 69.2%), Scotland (68.3% versus 66.3%) and Wales (70.6% versus 67.6%) and even with censoring, similar proportions of cases and controls had mention of one or more asthma admissions in the past year (34.0% versus 33.3%) and in the > 1e5 years prior (40.8% versus 42.5%). Table 2 displays odds ratios and 95% confidence intervals adjusted firstly for sex alone and then using the full confounder model. For the > 2e6 months prior, only SABA were positively associated with asthma death and although this association persisted in magnitude following full adjustment it fell short of statistical significance at the 5% level. A non-significant association of similar magnitude was observed for mention of SABA in the 2 months prior, providing a relatively consistent picture across the two time intervals. Fenoterol was rarely prescribed but in the 2 months prior it was mentioned in the notes of 4 cases but no controls.
There was a modest positive association between antimuscarinics mentioned in the 2 months prior and asthma death which persisted in magnitude after full adjustment but fell short of statistical significance at the 5% level. By contrast, after full adjustment, oral corticosteroids, injected corticosteroids and antibiotics mentioned in the 2 months prior were each associated with a significantly *p < 0.05, **p < 0.01, ***p < 0.001. Note: Due to censoring and the exclusion of one matched pair mapped to different countries based on GP post-code, analyses for the 2 months prior and the > 2e6 months prior were based on 516 and 526 matched pairs respectively. a Prescription Z mention of drug in primary care notes including computer printouts, referral letters, hospital discharge and outpatient letters. b Percentage of controls prescribed drug. c Additionally adjusted for age of asthma onset (including missings), mention of obesity ever, number of hospital admissions in the past year and > 1e5 years prior, mention of COPD in the past 5 years and mention of other chronic lung disease in the past 5 years, mention/prescription in the relevant time period of other asthma drug classes (inhaled corticosteroids, oral corticosteroids, inhaled short-acting beta 2 -agonists, inhaled long-acting beta 2 -agonists, antimuscarinics and methylxanthines) as appropriate and for any linear trend in deprivation rank within country.
d Mention of inhaled corticosteroids within 1 month either side of a mention of inhaled long-acting beta 2 -agonists but prior to index date; comparison group e no mention of inhaled longacting beta 2 -agonists. Final adjustment includes adjustment for mention/prescription of inhaled corticosteroids in the 2 months or > 2e6 months prior as appropriate.
lower risk of asthma death. However these three associations were not independent and when adjusted for each other (an extension of the full confounder model), the association with oral steroids became more consistent with a chance effect (OR Z 0.76 (95% confidence interval 0.55 to1.04)), while associations with antibiotics (OR Z 0.67 (0.49e0.91)) and injected steroids (OR Z 0.33 (0.14e0.80)) were little changed.
Even with full adjustment, there was no evidence of an overall association between LABA and asthma death whether mentioned in the 2 months (OR Z 0.89 (95% confidence interval 0.61 to 1.30)) or > 2e6 months prior (OR Z 1.08 (0.76e1.53)). Where LABA were mentioned in the primary care notes it was usual to find a mention of ICS within 1 month. Such evidence of concomitant prescribing was found in 86% of controls with a mention of LABA in the 2 months prior and 93% of controls with mention of LABA in the > 2e6 months prior. Fully adjusted odds ratios for LABA with and without concomitant mention of ICS were 0.92 (0.61e1.37) and 0.75 (0.32e1.78) respectively for the 2 month period and 1.05 (0.73e1.51) and 1.39 (0.53e3.65) for the > 2e6 month period but for both periods these differences were not statistically significant (p Z 0.671 and p Z 0.579 respectively). Table 3 displays odds ratios, and 95% confidence intervals adjusted for the full confounder model, extended to include age group interactions with sex, COPD and other chronic lung diseases. For the > 2e6 month period, odds ratios for Salmeterol differed significantly between the 1e44 and 45e64 year age groups as did the odds ratios for all LABA which were 0.63 (0.34e1.15) and 1.35 (0.90e2.03) respectively. There was no evidence of any similar age interaction with Salmeterol or all LABA when mentioned in the 2 months prior. Table 4 shows the results for the analysis of deprivation ranks, within each country. In the 2 months prior odds ratios for Salmeterol differed significantly across the 6 categories defined by country and within country deprivation rank. This finding appeared to be due to differences between deprivation groups within countries (p Z 0.023; df Z 3) rather than differences between countries (p Z 0.389; df Z 2) but given the lack of consistency in the direction of association within countries, it provides no coherent evidence of effect modification by deprivation.
Odds ratios for mention of SABA in the > 2e6 months prior provided little evidence of a positive association with mortality within Scotland or Wales but within England, odds ratios for the less and more deprived areas were 2.72 (1.48e5.00) and 1.56 (0.97e2.52) respectively. However differences across the 6 groups appeared to be due to differences between countries (p Z 0.003; df Z 2) rather than between deprivation groups within countries (p Z 0.437; df Z 3). Odds ratios for LABA mentioned in the > 2e6 months prior, exhibited a similar pattern to SABA, although for this variable the difference across all six groups was not statistically significant at the 5% level.
Discussion
In this fresh analysis of the ADCCS, we have used a dataset which has a higher level of detail and fewer potential biases than that used for the original report. Using different time references we have found, overall, a similar pattern of associations to those found by the previous analysis. In particular we found no evidence of any overall association between LABA and asthma death but some evidence that antibiotics and oral steroids when mentioned close to the index date, were associated with a lower risk of asthma death. A similar association with injected steroids is a new finding. Despite similarities with the original results, there are also material differences especially in terms of age group interactions which in the earlier report were only adjusted for sex. The results in this paper should therefore be viewed as replacing and adding to those previously published for the period 3 months prior to the index date.
Long-acting beta 2 -agonists (including salmeterol)
In this British study of severe asthmatics, there was no evidence that LABA, whether mentioned in the 2 or > 2e6 months prior, was associated with asthma mortality. Even for the > 2e6 month period, mention of LABA though consistent with up to a 53% higher risk of asthma death was also consistent with as much as a 24% lower risk (based on the upper and lower 95% confidence limits). This makes the finding of a significant age interaction in the > 2e6 months prior difficult to interpret especially as there was no significant odds ratio in either the 1e44 year or the 45e64 year age group.
There was no evidence that any association between LABA and mortality differed in a consistent fashion between those attending a GP surgery in a more or less deprived area. However our deprivation measures were somewhat limited, being neighbourhood rather than person specific, based on GP rather than patient post-code and relying on information which post-dated our study period e.g. Index of Multiple Deprivation for England 2004.
It has been suggested that any positive association between LABA and mortality might be reduced in the presence of ICS. 2, 14 In our study mention of LABA without a concomitant mention of ICS was uncommon. It has been suggested that this explains the lack of association between LABA and mortality reported in our previous analysis of this case-control study. However, it also means that if a modifying effect of ICS exists we have little statistical power to detect it. Odds ratios for LABA with and without ICS ( Table  2 ) add little to the debate as they do not provide a consistent pattern across the two time windows.
Inhaled short-acting beta 2 -agonists
In line with other studies 15e18 we found some evidence of a higher risk of asthma death associated with any mention of SABA in the > 2e6 months prior, an association which did not appear to be explained by our adjustment for potential confounding factors. Final adjusted odds ratios for mention in the 2 and > 2e6 months prior were similar in magnitude, though somewhat lower than the adjusted odds ratio of 2.05 (1.26e3.33) reported by our previous analysis of the > 1e5 years prior. 5 There was no evidence of a modifying effect of age or background levels of deprivation (based on GP post-code) but Note: Due to censoring and the exclusion of one matched pair mapped to different countries based on GP post-code, analyses for the 2 months prior and the > 2e6 months prior were based on 516 and 526 matched pairs respectively. a Adjusted for sex, an age group interaction with sex, age of asthma onset (including missings), mention of obesity ever, number of hospital admissions in the past year and > 1e5 years prior, mention of COPD in the past 5 years and mention of other chronic lung disease in the past 5 years (including age group interactions with COPD and other chronic lung diseases), mention/prescription in the 2 months prior of other asthma drug classes (inhaled corticosteroids, oral corticosteroids, inhaled short-acting beta 2 -agonists, inhaled long-acting beta 2 -agonists, antimuscarinics and methylxanthines) as appropriate and for any linear trend in deprivation rank within country.
b Prescription Z mention of drug in primary care notes including computer printouts, referral letters, hospital discharge and outpatient letters. c Within age group, percentage of controls prescribed drug. Note: Due to censoring and the exclusion of one matched pair mapped to different countries based on GP post-code, analyses for the 2 months prior and the> 2e6 months prior were based on 516 and 526 matched pairs respectively. a Adjusted for sex, age of asthma onset (including missings), mention of obesity ever, number of hospital admissions in the past year and > 1e5 years prior, mention of COPD in the past 5 years and mention of other chronic lung disease in the past 5 years, and mention/prescription in the > 2e6 months prior of other asthma drug classes (inhaled corticosteroids, oral corticosteroids, inhaled short-acting beta 2 -agonists, inhaled long-acting beta 2 -agonists, antimuscarinics and methylxanthines) as appropriate.
b Prescription Z mention of drug in primary care notes including computer printouts, referral letters, hospital discharge and outpatient letters. c Less Deprived Z deprivation rank (numerically) at or higher than the mid-rank for the country; More deprived Z deprivation rank (numerically) lower than the mid-rank for the country.
d Percentage of controls prescribed drug.
we unexpectedly found evidence in support of a modifying effect of 'country'. This comparison was not postulated a priori and should be viewed with caution. It may be due to chance or reflect real regional differences in: prescribing; record keeping (due to the use of 'mentions' rather than prescriptions); access to both primary and secondary care; and/or patient behaviour in terms of compliance and the severity threshold for seeking medical treatment.
Antimuscarinics and methylxanthines
Mention of antimuscarinics (predominantly ipratropium bromide) was associated with a higher risk of asthma death in the 2 months prior, an association that persisted in magnitude after full adjustment. Some other indications of a positive association between asthma death and ipratropium bromide, or the regular use of all antimuscarinics have been reported from the General Practice Research Database 18, 19 and a small case-control study. 20 However, as suggested in these studies, such associations may result from confounding by co-morbidity with COPD or by asthma severity. The latter may explain our findings as, based on BTS guidelines, 21 antimuscarinics were only prescribed to those with very severe asthma or whose asthma was not adequately controlled by high-dose ICS (Step 4).
We found no evidence of an association between methylxanthines and asthma death, even though, like antimuscarinics, these drugs were also reserved until Step 4. 21 
Inhaled corticosteroids
Regular use of ICS is well established as beneficial in preventing asthma exacerbations 22 and is associated with a lower risk of asthma admissions. 23, 24 However we found little evidence of an association between asthma death and ICS, although in the 2 months, > 2e6 months and in the > 1e5 years prior, 5 odds ratios, though non-significant, were of similar magnitude (0.86, 0.85, 0.86 respectively).
Oral and injected corticosteroids
Oral corticosteroids tend to be prescribed as a short 'rescue' course in response to an acute attack, or as maintenance (BTS Step 5) among severe asthmatics. 21 The inverse association observed both for oral corticosteroids and for injected corticosteroids in the 2 but not the > 2e6 months prior may therefore indicate the benefit of appropriate treatment in the immediate lead up to the index event.
Antibiotics
Mention of antibiotics in the 2 months prior was associated with a 32% lower risk of asthma death and although there was no evidence of an association in the > 2e6 months prior, the former was consistent with previously published results for the > 1e5 year period (OR Z 0.59). 5 This merits further investigation because there is little evidence in the literature to indicate whether or not antibiotics should be prescribed in the treatment of acute asthma without evidence of bacterial infection 25 and current guidelines clearly warn against over-use.
Study limitations
In this study we have gone to great lengths to obtain good quality data and to adjust for potential bias. Nevertheless, the quality and completeness of the information contained in the general practitioner notes was not within our control, leading us to base our drug variables on mention in the GP notes (Yes or No). Mention is not the same as prescription but in common with prescription is dependent on the level of use of primary and secondary care services. How to disentangle use leading to prescription or use increasing the likelihood of picking up a mention of a prescribed drug is problematic but to some extent will be adjusted for by the inclusion of other asthma drugs, prior hospital admissions and co-morbidity in our final model. As in all observational studies adjustment for confounding is important and in this new analysis we have introduced adjustment for deprivation in addition to markers of asthma severity and comorbidity. However, the possibility of confounding by other factors cannot be discounted. Finally given that we present results for two time periods it is important that we do not place too much emphasis on unexpected significant results which may be the spurious outcome of multiple testing.
Conclusion
While associations of oral corticosteroids, injected corticosteroids and antibiotics with a lower risk of asthma death may simply indicate the benefits of appropriate medication for an acute asthma episode or infective exacerbation, the geographic pattern of results observed for inhaled shortacting beta 2 -agonists though unexpected may point to differences in regional prescribing patterns and health service provision/utilisation. In a population of severe asthmatics in whom long-acting beta 2 -agonists and inhaled corticosteroids appeared to be commonly prescribed concomitantly, there was no evidence overall that long-acting beta 2 -agonists were associated with increased risk of asthma death. Las Casas, Shehla Begum and Rajeevi Senadheera for help with data entry. Finally we would like to acknowledge all those who contributed in the original study and on whose original work this entire project was based.
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